There are 3397 resources available
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03